BLPH — Bellerophon Therapeutics Share News
0.000.00%
Last trade - 00:00Bellerophon Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Tang Capital Partners Lp Reports 9.99% Passive Stake In Bellerophon Therapeutics Inc As Of March 7 - SEC Filing
Brief: Perceptive Advisors Reports 8.9% Passive Stake In Bellerophon Therapeutics
U.S. STOCKS ON THE MOVE-Snap, Spirit Airlines, Merck, C3.ai
Brief: Bellerophon Therapeutics Is Not Offering Any Shares Of Its Common Stock
Brief: Bellerophon Therapeutics Receives IND Clearance From China NMPA To Conduct Phase 3 Clinical Trial In China For INOpulse® In Fibrotic Interstitial Lung Disease
Bellerophon rises on nod to start trial in China
Bellerophon Therapeutics rises on enrollment completion for lung disease therapy trial
Brief: Bellerophon Therapeutics Announces Completion Of Enrollment In Late-stage Study For Type of Lung Disease therapy
U.S. STOCKS ON THE MOVE-Lamb Weston Foldings, Stitch Fix, Bellerophon Therapeutics
Bellerophon Therapeutics jumps on China commercialization deal
Brief: Bellerophon Therapeutics Announces License Agreement For The Commercialization Of Inopulse® In Greater China With Baylor Biosciences
Bellerophon Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Bellerophon Provides Clinical Program Update And Reports Third Quarter 2022 Financial Results
Bellerophon Therapeutics Inc expected to post a loss of 58 cents a share - Earnings Preview
Bellerophon up as FDA allows smaller patient group for lung disease drug study
Brief: Bellerophon Announces FDA Acceptance Of Change To Ongoing Phase 3 Rebuild Study Of Inopulse
Brief: Bellerophon Therapeutics reports Q2 results
Brief: Bellerophon Provides Clinical Program Update And Reports First Quarter 2022 Financial Results